Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 15/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276086 | 0.84 | L3MBTL1 (0.61) | ATMTDP1L3MBTL1 | |
| SCHEMBL2092938 | 0.84 | PTGIR (0.52) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL27449198 | 0.83 | PTGIR (0.58) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL7985347 | 0.81 | NPC1 (0.51) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL2094984 | 0.81 | NPSR1 (0.48) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL2094982 | 0.80 | PTGIR (0.47) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL2093371 | 0.79 | MEN1 (0.43) | PTGIRATMTDP1L3MBTL1TACR3 | |
| SCHEMBL1118819 | 0.78 | PTGIR (0.46) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| Methyl Carbamate SCHEMBL11287154 | 0.76 | L3MBTL1 (0.52) | ATMTDP1L3MBTL1 | |
| SCHEMBL6294911 | 0.76 | PTGIR (0.53) | PTGIRPTGDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PTGIR 1605/4885PTGDR 427/4885PTGER4 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.